Sector News

Vanda Pharmaceuticals prepares to explore a sale

September 26, 2016
Life sciences

Vanda Pharmaceuticals Inc, a U.S developer of medicines for the central nervous system, is preparing to consider strategic alternatives including a potential sale, according to people familiar with the matter.

The move illustrates how Vanda is seeking to capitalize on an anticipated wave of deal making in the sector. Advances in treating several serious neurological diseases have attracted interest and resources from major drug makers.

Vanda is holding conversations with investment banks about appointing a financial adviser to help it review its options, the people said this week. Vanda has explored selling itself in the past, and there is no certainty the latest move will result in any deal, the people cautioned.

The sources asked not to be identified because the deliberations are confidential. Vanda declined to comment. The company’s shares jumped as much as 16 percent on the news and ended trading on Thursday up 7 percent at $16.62, giving Vanda a market capitalization of $719 million.

Washington, D.C.-based Vanda makes two neurological drugs, Hetlioz and Fanapt, which treat sleep disorders and schizophrenia, respectively. Together, they brought in about $100 million in revenues in 2015.

Vanda is researching wider indications for Hetlioz, including its potential use in treating sleep disturbances associated with Smith-Magenis syndrome, a rare genetic disorder.

Vanda is also working on a drug that has the potential to treat a severe form of dermatitis. It is in phase two clinical trials.

Earlier this summer, a court ruled in favor of Vanda in its lawsuit against Roxane Laboratories Inc, a generic drug maker that challenged Fanapt’s patent protection. Vanda now enjoys patent protection for Fanapt through 2027.

In a sign that deal making in the sector is picking up, Arbor Pharmaceuticals acquired XenoPort Inc, a developer of neurological drugs, in July for $467 million, a 60 percent premium to the closing price of its shares before the deal was signed.

Several other central nervous system drug makers have attracted takeover interest in recent weeks, including GW Pharmaceuticals Plc, which has a drug that promises to treat rare forms of epilepsy, Reuters reported earlier this month.

Depomed Inc, whose drug Nucynta treats pain, is also preparing to explore a sale, Reuters reported last week.

In recent months, Allergan Plc, one of the biggest players in the central nervous system sector, has been seeking to deploy around $20 billion in cash gleaned from a recent deal with Teva Pharmaceuticals.

By Carl O’Donnell

Source: Reuters

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).